Bioactive Polyurethane Shape Memory Polymer Foam Dressings with Enhanced Blood and Cell Interactions for Improved Wound Healing
Source abstract
Abstract
Polyurethane (PUr) shape memory polymer (SMP) foams have demonstrated excellent bleeding control in traumatic wounds. Unlike the current clinically available treatment options, PUr SMP foams can address noncompressible bleeds, are safe for prolonged use, and are highly tunable, offering broad functionalities like biodegradation and antimicrobial properties. Despite their hemostatic efficacy, PUrs are entirely synthetic, which limits their long-term healing capacity if left in a wound to degrade. This work employed methods for facile incorporation of bioactive collagen and gelatin into PUr foams postfabrication to enhance their clotting efficacy and drive cell interactions. The procoagulant nature of collagen and gelatin increased the clotting accomplished by the PUr SMP foams. Additionally, the bioactive PUr SMP foams promoted cell attachment, spreading, and proliferation on foam pores, which could facilitate tissue migration into the scaffold and promote wound repair. Overall, a bioactive PUr SMP foam dressing could significantly improve traumatic wound healing outcomes.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Polymer composites and self-healing · Wound Healing and Treatments · Electrospun Nanofibers in Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Biomedical and Chemical Engineering and BioInspired Syracuse: Institute for Material and Living Systems
Syracuse University
Funding
National Science Foundation Graduate Research Fellowship Program · Shape Memory Medical · National Heart, Lung, and Blood Institute · Congressionally Directed Medical Research Programs
References (69)
Show source-provided references
1. 10.1016/j.recm.2023.07.00410.1016/j.recm.2023.07.004 ↗
2. 10.1016/j.bioactmat.2020.10.00210.1016/j.bioactmat.2020.10.002 ↗
3. 10.1021/bk-2023-1454.ch00810.1021/bk-2023-1454.ch008 ↗
4. 10.1533/9781908818188.11510.1533/9781908818188.115 ↗
5. 10.1039/b922943d10.1039/b922943d ↗
6. 10.1039/C6TB01690A10.1039/C6TB01690A ↗
7. 10.1016/j.actbio.2018.11.03110.1016/j.actbio.2018.11.031 ↗
8. 10.1002/lsm.1000710.1002/lsm.10007 ↗
9. 10.1073/pnas.060007910310.1073/pnas.0600079103 ↗
10. 10.1002/pat.362110.1002/pat.3621 ↗
11. 10.1039/b923717h10.1039/b923717h ↗
12. 10.1136/neurintsurg-2022-01899610.1136/neurintsurg-2022-018996 ↗
13. 10.1186/s42155-021-00214-w10.1186/s42155-021-00214-w ↗
14. 10.1016/j.actbio.2021.10.00510.1016/j.actbio.2021.10.005 ↗
15. 10.1002/cphc.20170101510.1002/cphc.201701015 ↗
16. 10.1021/acsabm.1c0051610.1021/acsabm.1c00516 ↗
17. 10.1002/jbm.a.3738310.1002/jbm.a.37383 ↗
18. 10.1016/j.actbio.2025.02.02710.1016/j.actbio.2025.02.027 ↗
19. 10.3390/ijms1704054510.3390/ijms17040545 ↗
20. 10.1021/acsabm.8b0065010.1021/acsabm.8b00650 ↗
21. 10.1016/j.actbio.2013.09.02710.1016/j.actbio.2013.09.027 ↗
22. 10.1002/app.5001710.1002/app.50017 ↗
23. 10.1002/jbm.b.3456410.1002/jbm.b.34564 ↗
24. 10.3390/polym1205119110.3390/polym12051191 ↗
25. 10.1002/term.278410.1002/term.2784 ↗
26. 10.1039/D3TB00120B10.1039/D3TB00120B ↗
27. 10.3390/polym1314231910.3390/polym13142319 ↗
28. 10.3389/fphar.2024.139893910.3389/fphar.2024.1398939 ↗
29. 10.1111/j.1538-7836.2004.00665.x10.1111/j.1538-7836.2004.00665.x ↗
30. 10.1016/j.biomaterials.2010.03.064.Cell-laden10.1016/j.biomaterials.2010.03.064.Cell-laden ↗
31. 10.1016/j.jmbbm.2016.06.01910.1016/j.jmbbm.2016.06.019 ↗
32. Kim S. W. · Trans. Am. Soc. Artif. Int. Organs · 1974 · 20 · 449
33. 10.1016/S0026-2862(03)00040-210.1016/S0026-2862(03)00040-2 ↗
34. 10.1080/05704928.2018.142659510.1080/05704928.2018.1426595 ↗
35. 10.1039/D3GC03302C10.1039/D3GC03302C ↗
36. 10.1021/ja00084a06710.1021/ja00084a067 ↗
37. 10.1177/019262331038947410.1177/0192623310389474 ↗
38. 10.1161/ATVBAHA.107.14191110.1161/ATVBAHA.107.141911 ↗
39. 10.3390/polym1323408410.3390/polym13234084 ↗
40. U.S. Food & Drug Administration. Use of International Standard ISO 10993–1 · U.S. Dep. Heal. Hum. Serv. Food Drug Adm. · 2020 · 1
41. 10.2147/CCID.S5004610.2147/CCID.S50046 ↗
42. 10.3390/polym1317295910.3390/polym13172959 ↗
43. 10.1517/14712598.2013.84819310.1517/14712598.2013.848193 ↗
44. 10.1016/j.ijbiomac.2024.13825410.1016/j.ijbiomac.2024.138254 ↗
45. 10.1016/j.ijscr.2020.09.11310.1016/j.ijscr.2020.09.113 ↗
46. 10.3390/ijms24131054010.3390/ijms241310540 ↗
47. 10.1016/j.jocn.2021.05.01610.1016/j.jocn.2021.05.016 ↗
48. 10.1007/978-3-642-00418-6_312210.1007/978-3-642-00418-6_3122 ↗
49. 10.3390/cells1003066210.3390/cells10030662 ↗
50. 10.21037/jtd.2019.06.5910.21037/jtd.2019.06.59 ↗
51. 10.1002/mame.20160046010.1002/mame.201600460 ↗
52. 10.1093/burnst/tkab01910.1093/burnst/tkab019 ↗
53. 10.1016/j.wneu.2021.07.01210.1016/j.wneu.2021.07.012 ↗
54. 10.1021/acs.biomac.2c0092410.1021/acs.biomac.2c00924 ↗
55. 10.1002/adfm.20242295710.1002/adfm.202422957 ↗
56. 10.3390/pharmaceutics1507183610.3390/pharmaceutics15071836 ↗
57. 10.5339/gcsp.2013.3810.5339/gcsp.2013.38 ↗
58. 10.1016/j.carbpol.2024.12240910.1016/j.carbpol.2024.122409 ↗
59. 10.1021/acsomega.2c0673010.1021/acsomega.2c06730 ↗
60. 10.3390/polym1521430110.3390/polym15214301 ↗
61. 10.3390/pharmaceutics1312212710.3390/pharmaceutics13122127 ↗
62. 10.1002/pi.644110.1002/pi.6441 ↗
63. 10.1093/nsr/nwac16210.1093/nsr/nwac162 ↗
64. 10.21037/atm-20-545210.21037/atm-20-5452 ↗
65. 10.1016/j.msec.2016.10.01910.1016/j.msec.2016.10.019 ↗
66. 10.3389/FBIOE.2022.809361/FULL10.3389/FBIOE.2022.809361/FULL ↗
67. 10.1080/00914037.2021.201831610.1080/00914037.2021.2018316 ↗
68. 10.1186/s13036-023-00364-610.1186/s13036-023-00364-6 ↗
69. 10.1016/j.tice.2023.10209110.1016/j.tice.2023.102091 ↗